3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
83
Neoplasm Metastasis
7
Neoplasms
6
Sarcoma
4
Squamous Cell Carcinoma of Head and Neck
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Untreated Operable Early Breast Cancer
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Somatostatinoma
1
Solid Tumors
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Interventions
Imatinib Mesylate
3
Radiotherapy
2
Nivolumab
2
relatlimab
1
palbociclib
1
nilotinib
1
Surveys and Questionnaires
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Radiation
1
Proton Therapy
1
Photochemotherapy
1
Pemetrexed
1
Immunoglobulin G
1
Disulfides
1
Dihematoporphyrin Ether
1
Dasatinib
1
Cyclophosphamide
1
Blood Specimen Collection
1
Bacterial Load
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Chordoma
×
palbociclib
×
Clear all
NCT03110744
2023-03-27
NCT-PMO-1601
University Hospital Heidelberg
Phase 2
Completed
43 enrolled